Dividends Inside 
Thermo Fisher Scientific Inc.
TMO
$523.44 (+ $10.11 + 1.97%)
Last updated: 2026-07-04 03:08 UTC
Thermo Fisher Scientific Inc. trades under ticker TMO on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US8835561023, CUSIP 883556102.
About the Company
Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents. The company operates through four main segments: analytical technologies, which focuses on advanced instrumentation for research and analysis; specialty diagnostic products for clinical and healthcare applications; life science solutions offering reagents and tools for biological research; and lab products and services, including contract research organization services to support scientific workflows. These offerings enable advancements in healthcare, pharmaceuticals, biotechnology, and academic research by delivering high-quality tools for discovery, development, and production processes. Thermo Fisher Scientific Inc. serves a global customer base across research institutions, pharmaceutical companies, diagnostics providers, and industrial sectors, facilitating innovation in drug development, genomics, proteomics, and clinical diagnostics. Founded in 2006 and headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. plays a pivotal role in enabling scientific breakthroughs and operational efficiency in life sciences and healthcare markets.
Price History
Latest News for TMO
Thermo Fisher Scientific acquires Clario for nearly $8.9bn
Clario will become part of Thermo Fisher’s laboratory products and biopharma services segment.
Thermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions
RIDGEFIELD, N.J., March 25, 2026--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a strategic collaboration with SHL Medical, a leading provider of advanced drug delivery systems, alongside an expansion of sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, NJ site. Together, these investments establish a fully integrated U.S.-based offering spanning sterile manufacturing, device assembly and commercial packaging for drug-device com
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. On March 2, 2026, AIM ImmunoTech announced entering into an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design a pivotal Phase 3 clinical trial for Ampligen. The study will […]
Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.
WALTHAM, Mass., March 24, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the completion of its acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earnout and other payments, largely dependent on performance. With the transaction complete, the Clario business will become part of Thermo Fisher’s Laboratory Products and Biopharma Services
Is Thermo Fisher Scientific (TMO) Pricing Look Attractive After Recent Share Price Weakness
Thermo Fisher Scientific might already be on your watchlist, but the real question is whether the current share price around US$474 reflects what you are actually getting for your money. Recent share price moves have been mixed, with the stock up 2.2% over the last week, while the 30 day return is a 7.2% decline and the year to date return sits at a 19.9% decline, contributing to a 1 year return of an 8.0% decline and a 3 year return of a 14.2% decline. These returns sit against an ongoing...
U.S. Exosomes Market to Skyrocket During 2026-2033, Reaching $716.8 Million - Analysis of Lucrative Business Opportunities and Key Players; Danaher, Thermo Fisher Scientific, Hologic, Fujifilm, Lonza and More
U.S. Exosomes Market U.S. Exosomes Market Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The "U.S. Exosomes Market Size, Share & Trends Analysis Report by Product & Service, Application, Workflow, End Use, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.The U.S. exosomes market size, valued at USD 115.6 million in 2025, is projected to surge to USD 716.8 million by 2033, marking a robust CAGR of 25.75% from 2026 to 2033. The market's expansion is largely driven